观察转基因细胞SPC-A-1/IL-2的致突变作用，为转基因肿瘤细胞作为瘤苗进行临床应用的安全性检测提供依据。方法：在人IL-2的cDNA与逆转录病毒载体pLXSN重组并完成PA317/pLIL-2SN包装体系的基础上，将IL-2基因导入人肺腺癌胸膜转移细胞系SPC-A-1中并得到IL-2基因的稳定表达，然后通过遗传毒理学实验技术对转基因细胞SPC-A-1/IL-2的DNA及培养上清液进行体内和体外的致突变性实验研究。结果：转基因细胞SPC-A-1/IL-2的DNA及培养上清液均未显出致突变作用。结论： 转基因细胞SPC-A-1/IL-2作为瘤苗应用可初步视为是安全可靠的。

To investigate the safety of transgenic human lung adenocarcinoma cell line SPC-A-1/IL-2 as tumor vaccine. Methods: IL-2 gene was introduced into human lung adenocarcinoma cell line SPC-A-1 and was expressed stably on the basis of the construction of retroviral packing cell line PA317/pLIL-2SN. The mutagenesis of both the DNA and supernatant of SPC-A-1/IL-2 in vivo and in vitro was tested by means of genetic toxicological techniques. Results: The result indicated that mutagenesis of both the DNA and the supernatant of transgenic cell SPC-A-1/IL-2 was not observed. Conclusion: The initial experiment suggested that the application of transgenic cell SPC-A-1/IL-2 as tumor vaccine was bisically safe and reliable.

* 本研究受国家“九?五”攻关课题基金(96-906A-01-20)资助